-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-Live Mint An investigation found DCGI cleared drugs without conducting mandatory clinical trials After five rounds of consultations in six months, a committee tasked with making recommendations on cleaning up India’s drugs-approval process and ending the cosy relationship between doctors, pharmaceutical companies and government officials had no suggestions to offer by way of a crackdown. It has, instead, suggested setting up 20 sub-committees. The report submitted to the health ministry in November is...

-The Hindu India’s drug price control order, which is vital to the availability of affordable essential medicines, has been whittled down to the point of becoming insignificant. While the number of price-controlled medicines has dwindled over the past three decades, from 347 to 74, the pharmaceutical industry has been pursuing super profits. The High Level Expert Group of the Planning Commission on Universal Health Coverage noted in its report that price...

-The Business Standard If the Cabinet clears the proposed policy, the Department of Pharmaceuticals would have to notify this before the SC?s next hearing on the matter on Nov 27 The Cabinet is likely to take up the proposed National Pharmaceutical Pricing Policy tomorrow, government sources said. The policy is aimed at capping the prices of 348 essential medicines at the weighted average of all drugs in a particular segment, with...

-The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control —...